GlaxoSmithKline UK Ltd

Stockley Park West
Uxbridge
Middlesex
UB11 1BT

Tel. +44 (0)20 8990 9000
Fax. +44 (0)20 8990 4321
www.gsk.com

19th February 2018

GLAXOSMITHKLINE SAFETY ADVISORY

Reminder letter regarding the discontinuation of Eperzan▼(albiglutide)

Subject: Discontinuation of EPERZAN (albiglutide)

Dear Healthcare Professional,

Following prior communication by GSK in September 2017, this is a targeted reminder letter that GSK will discontinue the commercial sale and availability of Eperzan worldwide. Commercial supplies will no longer be available in the UK from 1st July 2018.

You are being sent this reminder because you have dispensed Eperzan from your pharmacy in recent months, following our earlier communication in September 2017. Please note the following:

Suggested Actions

1: Initiate discussions with patients currently on Eperzan with a plan to transition all patients to an alternative therapy as soon as possible and prior to end of June 2018

2: Do not initiate treatment for any new patients

3: Ensure your practice team and the relevant prescriber are aware of this information

Background and further information

Eperzan▼ (albiglutide) subcutaneous injections (30 mg and 50 mg) have been licenced in the UK since 2014 for adults with type 2 diabetes mellitus. **This withdrawal is on commercial grounds only, and is not related to efficacy or safety of the medicine.** GSK has also communicated this decision to the EMA and the MHRA.

If you have any questions, please contact the Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221441

For medical information enquiries please email ukmedinfo@gsk.com or call 0800 221 441 (option 4)

Yours sincerely,

Dr Will Spencer MA (Cantab) MBBS MRCPCH MFPM
UK Medical Director IRDBU
Immunology, Diabetes and Rare Diseases Business Unit

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

This letter is not a comprehensive description of the risks with the use of EPERZAN. Please refer to the Summary of Product Characteristics available at http://www.medicines.org.uk/emc/